As you probably know, Evaluate has an incredibly rich and comprehensive set of data and insight about the pharma market. This means we’re able to produce some really valuable reports, webinars and articles that provide insight around the most exciting areas of the industry. And we create rather a lot of them, which can make it hard to keep up with it all.

To help, we’ve pulled together some of the key pieces of content that we’ve published so far in 2025. Think of it as a Greatest Hits album – all the best bits in one, easy to absorb compilation.

1. 2025 Preview: If you missed our look at the catalysts for the year ahead, you really should check it out. It’s packed with data and insights about what to expect from pharma in 2025. We include our forecasts for the top-selling drugs, the fastest growing therapies and the pipeline drugs waiting in the wings. Inevitably, we touch on the potential impact of the Trump administration and the evolving role of China too. There’s loads of content around the report, so the best move is to head over to our content hub to find it all in one place.
2. 2024 Review: Looking forward is critical but it’s useful to understand the past year as well. In this report, we look at the dealmaking, IPO and financing situation in 2024. We also investigate the stock market winners and losers in mid-cap biopharma, and ask why only half of the year’s biggest launches belonged to Big Pharma. Check it out here.
3. The Forecaster’s Guide to Long-Range Planning: Forecasting is a tricky business at the best of times, but long-range forecasting comes with even more challenges. And our forecasting experts investigated some of these challenges in our recent webinar. It’s a must-watch if you’re in the long-range planning cycle now, and a great way to learn about some of the models and methodologies that our experts recommend. You can find it on-demand here.
4. Biotech Sponsors Dominate 2024 FDA Approvals: Investigating the “biotech boost”, this article provides some fascinating insights into the drivers behind 2024’s flurry of new approvals from smaller players. We look at the key FDA approvals last year and analyze the modalities where biotechs are thriving. It’s a pretty quick, but really insightful read.
5. Key Forecasting Trends Shaping Pharma in 2025: Another one for those tasked with forecasting this year. Our report looks at the key trends in forecasting, including the role of artificial intelligence on drug development and the need for more adaptable, technology-driven forecasting solutions. A must-read to stay on top of your forecasting game this year.

Are there any topics or insight about the pharma market you’d like us to cover this year? If so, drop us a note at [email protected] and we’ll see what we can do. And remember that you can find more great material covering areas like clinical trials and market access over at Norstella.com.